 A human trial suggests clearing plaques slows mental decline. At the 15th International Conference on Alzheimer's and Parkinson's Diseases, Dr. Mark Minton of Eli Lilly presented data on the performance of the anti-amyloid drug, Dynanemab. While the patients did not get better, the administration of Dynanemab appeared to slow decline by an average of 32% in combined assessment of cognitive and functional decline. The results show that Dynanemab was able to remove the plaques associated with Alzheimer's in the majority of trial participants, while also reducing the accumulation rate of neurofibrillary tangles in the frontal cortex and other regions. The results of the trial suggest that treatments aimed at amyloid can slow cognitive decline and modify the progression of Alzheimer's. But the fact that the treatment didn't improve or reverse conditions could indicate that targeting amyloid alone isn't enough. See the full video at youtube.com backslash x10 show.